ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CERS / forecast
BWAY (44) SSII (30) RCEL (46) DCTH (59) ⌘ Pro Terminal →

Cerus Corporation (CERS) 12-Month Stock Forecast & Price Target Cone

$2.36 +3.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.37

Cerus Corporation (CERS) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $459.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CERS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Cerus Corporation (NASDAQ: CERS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $2.36 (+3.51% 1D, market cap $459.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CERS ranks #884 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CERS compare to BWAY and SSII in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), CERS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.5%. By comparison, BWAY (BrainsWay Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $455.9M) and SSII (SS Innovations International Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $471.1M). Among the 5-stock peer group, CERS leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CERS?
▼

Per CERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001020214), Cerus Corporation generated $233.8M in revenue (+16.1% YoY), -$15.6M in net income, and $1.1M in free cash flow against $221.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.37 (+0.44%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510027
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (4)Whales (5)SEC (8)Macro (5)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-14% Base Target
$4 Bull$2 Base$2 Bear
📬 FREE CERS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CERS)Realized 20D OHLCV Swing Band: ±8.1%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY CERS SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 6/9

▲ #2 Bullish Driver: Whale & Options Positioning+5/20 pts (19% of score)

20D Institutional Volume Accumulation (±8.1% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
19
Grade E$2.26+2.2% Next Q
Q2 (-2Q)
22
Grade E$2.31+3.9% Next Q
Q3 (-1Q)
24
Grade E$2.40-1.7% Next Q
Current
27
Grade E$2.36-10.3% Hist 90D α
Trajectory: E (19) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CERS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CERS currently carries a cautious 27/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.45) and Max Pain ($2.48) forces dealer call-delta covering toward $3.64.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CERS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CERS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CERS Position Size: $10,000

Shares at $2.36: 4237.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $1.58
$6,695
$-3,305 (-33.1%)
12M Consensus BaseTarget $2.03
$8,602
$-1,398 (-14.0%)
12M Bull Case BreakoutTarget $3.64
$15,424
+$5,424 (+54.2%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$369%B
JP MorganUS Large-Cap ResearchSELL$258%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CERS)

  • ✓Walkthrough of CERS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CERS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.24%⚡ TESTING RESISTANCE
2026-11-03O $2.44H $2.44L $2.28C $2.36VOL 1.50M
RES: $2.44SUP: $2.13SMA50: $2.45SMA200: $2.45
$3.59$3.10$2.61$2.13$1.64RES $2.44SUP $2.13$2.362026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CERS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CERS Butterfly Map → + Track CERS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +16.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CERS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CERS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CERS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CERS)

Health Care Rank #884 of 1015 ⚔️ BWAY vs CERS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CERS vs. BWAY, SSII, RCEL, DCTH)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cerus Corporation (CERS) ranks #884 by composite RQD confidence (27/100, grade E) and #457 by equity capitalization ($459.5M). Within this direct 5-issuer industry benchmark cohort, CERS leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with CERS at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CERS ACTIVE
Cerus Corporation
E 27/100 — — -15.5% +3.51% $459.5M Benchmark Subject
BWAY
BrainsWay Ltd.
D 44/100 — — — -2.38% $455.9M /bway-vs-cers →
SSII
SS Innovations International Inc.
E 30/100 — 46.0% -18.5% -1.70% $471.1M /ssii-vs-cers →
RCEL
Avita Medical Inc.
D 46/100 — 82.1% -35.0% -1.53% $484.0M /rcel-vs-cers →
DCTH
Delcath Systems Inc.
C- 59/100 — 86.2% 0.8% +1.78% $487.2M /dcth-vs-cers →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001020214 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cerus Corporation (CERS) reported GAAP revenue of $233.8M (+16.1% vs. FY2024 revenue of $201.3M , and +25.2% cumulative change since FY2023) , GAAP net income of -$15.6M, operating cash flow of $4.8M, and free cash flow of $1.1M (-87.0% YoY). On the balance sheet, CERS closed FY2025 with $221.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $233.8M -$15.6M $4.8M $1.1M $221.9M —
FY2024 (FY) 2024-12-31 $201.3M -$20.9M $11.4M $8.5M $200.9M —
FY2023 (FY) 2023-12-31 $186.8M -$37.5M -$43.2M -$43.2M — —

3. CERS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cerus Corporation (NASDAQ: CERS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $2.36 (+3.51% 1D, market cap $459.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CERS ranks #884 in composite RQD confidence.

How does CERS compare to BWAY and SSII in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CERS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.5%. By comparison, BWAY (BrainsWay Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $455.9M) and SSII (SS Innovations International Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $471.1M). Among the 5-stock peer group, CERS leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CERS?

Per CERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001020214), Cerus Corporation generated $233.8M in revenue (+16.1% YoY), -$15.6M in net income, and $1.1M in free cash flow against $221.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CERS trading relative to its 50-day, 200-day, and 52-week technical levels?

CERS last traded at $2.36 (+3.51% on volume of 3,985,004 shares), positioning the stock -3.67% below its 50-day simple moving average ($2.45) and -3.67% below its 200-day simple moving average ($2.45). Across its 52-week range of $1.38 to $3.47, CERS sits at the 46.9% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±8.1% ($2.17 to $2.55).

Direct Sub-Reports: CERS RQD Cockpit CERS 12M Forecast CERS Earnings & Move CERS Dividends & DRIP CERS Insiders & 13F CERS Whale Options CERS Profit Sankey CERS News & Why
ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ SEC XBRL & RQD VERIFIED

CERS — Cerus Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cerus Corporation (CERS) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.36 (+3.51% 1D, market capitalization $459.5M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -15.5%, gross margin of —, operating margin of -3.7%, and free cash flow yield of 0.23%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cerus Corporation (CERS) is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. The profile identifies the company's market capitalization as $0.5B. — Specific product lines, customer base, and revenue-generation model are not described in the provided sources.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cerus Corporation (CERS) reported $233.8M in annual revenue (up from $201.3M in FY2024, +16.1% YoY) and -$15.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($186.8M revenue, -$37.5M net income) through FY2025, CERS scaled operating cash flow to $4.8M and free cash flow to $1.1M, backed by $221.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.23% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $1.38 – $3.47 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -3.7% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph records supply_chain as NONE, with an empty set of butterfly links and an empty set of proprietary signals. No upstream or downstream dependencies, sector correlations, or 2nd-order bottlenecks are identified in the provided sources.

  • Key Question #1: Can CERS sustain or expand its -3.7% operating margin and -15.5% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $233.8M and free cash flow of $1.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CERS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CERS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cerus Corporation (CERS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CERS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CERS Bull vs. Bear Conversation Board — What's Your Call at $2.36?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CERS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CERS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $2.99 (+31.1%)
📌 Pinned Debate

Revenue grew from $186.8M in FY 2023 to $233.8M in FY 2025 while net losses narrowed from -$37.5M to -$15.6M.

Don't sleep on CERS's setup in Health Care. Revenue grew from $186.8M in FY 2023 to $233.8M in FY 2025 while net losses narrowed from -$37.5M to -$15.6M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (27/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@MacroHawk_NYC Agree on the RQD 27/100 quality, though with 1.0 beta I'm scaling in with half-size at $2.28 and keeping dry powder in case we test $2.12.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $1.82 (-20.2%)
Spot @ $2.28

The Roarable RQD rating scores the company 30 with an E grade, and the Altman Z-Score of 0.2 signals elevated distress risk.

I respect the product at Cerus Corporation, but the stock at $2.28 is a different story. The Roarable RQD rating scores the company 30 with an E grade, and the Altman Z-Score of 0.2 signals elevated distress risk.. FCF yield is 0.23% and RQD sits at 27/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%